BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
12. September 2024 16:56 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
27. Februar 2024 15:52 ET
|
BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
15. März 2021 11:12 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
15. November 2020 19:35 ET
|
BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
21. Mai 2020 13:58 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair
27. April 2020 01:15 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin...